FDA has issued a new reminder to compounders regarding the legal limits on compounding GLP-1-related drugs, including products involving semaglutide and tirzepatide, as the national supply of these medications begins to stabilize. The April 1, 2026 statement is significant for both traditional c...
Blog
The FDA's Peptide Reclassification: What's Coming, What It Means, and Why Compounding Pharmacies Should Pay Attention
The FDA's Peptide Reclassification: What's Coming, What It Means, and Why Compounding Pharmacies Should Pay Attention Published: March 12, 2026 This article is for informational purposes only and does not constitute legal advice. Consult a licensed attorney for guidance specific to your practic...
Educational Webinars, Videos, Presentations: How to Provide Compliant and Valuable Educational Content to Providers
Compounding pharmacies producing and distributing educational videos to healthcare providers on the benefits and uses of specific compounded drugs face a regulatory minefield of compliance considerations. Understanding these considerations can help pharmacies remain compliant with federal and state regulations while providing valuable educational content.
Tirzepatide Compounding Update
The FDA has stated that it does not intend to take action against compounders for violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) arising from conditions that depend on tirzepatide's inclusion on the FDA drug shortage list. Compounding pharmacies should still exercise their own ...